Company profile
EnsiliTech
EnsiliTech is a biotechnology start-up developing ensilication, a platform technology, to remove the need for refrigeration when transporting and storing vaccines and biologicals
Financial period: 1 Aug 2023 to 31 Jul 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
CS01 | Transaction MzQzMTgwMDIxMGFkaXF6a2N4
Published 11 Aug 2024 16:59
Company registered at Companies House
1 Feb 2025 to 31 Jan 2027
Currently antibody medicines require ultra-cold-chain during production and storage to prevent spoiling due to aggregation at the molecular level, which can occur at any stage from factory to patient. This project uses game-changing, proprietary Ensilication technology to remove this cold-chain dependence in the manufacturing and supply of antibody treatm...
1 Oct 2023 to 30 Sep 2025
EnsiliTech working with Afrigen and Emervax intend to develop a thermostable ensilicated messenger ribonucleic acid in lipid nanoparticle (mRNA-LNP) vaccine against the Hantaan virus (HTNV) that can be rapidly and equitably deployed globally. The Hantaan virus of the hantavirus family is predominantly present in Asia, although it occurs around the globe. ...
1 Feb 2022 to 31 Jan 2023
Vaccines are known to be the most effective medical innovation in human history, credited with saving over 10 million lives since 1962\. The significant challenge with vaccines however is that they have to be kept refrigerated, between 2-8°C, at all times during their storage and transport, requiring a global infrastructure of refrigeration equipment know...
